Literature DB >> 22434536

Intrapancreatic delivery of human umbilical cord blood aldehyde dehydrogenase-producing cells promotes islet regeneration.

G I Bell1, D M Putman, J M Hughes-Large, D A Hess.   

Abstract

AIMS/HYPOTHESIS: We sought to investigate the stimulation of islet regeneration by transplanted human umbilical cord blood (UCB) cells purified according to high aldehyde dehydrogenase (ALDH) activity (ALDH(hi)), a conserved characteristic of multiple progenitor lineages. We hypothesised that direct intrapancreatic (iPan) delivery of ALDH(hi) progenitors would augment islet regeneration via timely and localised exposure to islet-regenerative stimuli.
METHODS: Cells were purified from UCB based on flow cytometry for low ALDH activity (ALDH(lo)) vs ALDH(hi). UCB ALDH(lo) or ALDH(hi) cells were compared for surface marker expression, as well as haematopoietic, endothelial and multipotent stromal progenitor content in vitro. UCB ALDH(lo) or ALDH(hi) cells were i.v. or iPan injected into streptozotocin-treated non-obese diabetic/severe combined immune-deficient mice temporally monitored for blood glucose, serum insulin and glucose tolerance. Human cell recruitment and survival in the pancreas, insulin content, islet-associated cell proliferation and islet vascularisation were documented in situ.
RESULTS: UCB-derived ALDH(hi) cells were highly enriched for haematopoietic and endothelial progenitor frequency, and showed increased expression of progenitor and myeloid cell surface markers. Although i.v. transplantation of ALDH(hi) cells demonstrated low pancreas engraftment and only transient blood glucose lowering capacity, iPan injected ALDH(hi) cells reversed established hyperglycaemia, increased serum insulin and improved the response to a glucose challenge. iPan injected ALDH(hi) cells surrounded damaged islets at early time points and increased islet-associated cell proliferation, resulting in the recovery of beta cell mass. CONCLUSIONS/
INTERPRETATION: iPan delivery of UCB ALDH(hi) cells potentiated islet-associated cell proliferation, insulin production and islet revascularisation, resulting in the recovery of host islet function. Elucidation of the progenitor-specific pathways stimulated during islet regeneration may provide new approaches to promote islet expansion during diabetes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22434536     DOI: 10.1007/s00125-012-2520-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  10 in total

1.  Bone marrow-derived stem cells initiate pancreatic regeneration.

Authors:  David Hess; Li Li; Matthew Martin; Seiji Sakano; David Hill; Brenda Strutt; Sandra Thyssen; Douglas A Gray; Mickie Bhatia
Journal:  Nat Biotechnol       Date:  2003-06-22       Impact factor: 54.908

2.  Transplanted human bone marrow progenitor subtypes stimulate endogenous islet regeneration and revascularization.

Authors:  Gillian I Bell; Heather C Broughton; Krysta D Levac; David A Allan; Anargyros Xenocostas; David A Hess
Journal:  Stem Cells Dev       Date:  2011-10-21       Impact factor: 3.272

3.  Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I.

Authors:  E Snarski; A Milczarczyk; T Torosian; M Paluszewska; E Urbanowska; M Król; P Boguradzki; K Jedynasty; E Franek; W Wiktor-Jedrzejczak
Journal:  Bone Marrow Transplant       Date:  2010-06-28       Impact factor: 5.483

4.  Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice.

Authors:  Ryang Hwa Lee; Min Jeong Seo; Roxanne L Reger; Jeffrey L Spees; Andrey A Pulin; Scott D Olson; Darwin J Prockop
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-06       Impact factor: 11.205

5.  Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study.

Authors:  Hillary A Keenan; Jennifer K Sun; Jared Levine; Alessandro Doria; Lloyd P Aiello; George Eisenbarth; Susan Bonner-Weir; George L King
Journal:  Diabetes       Date:  2010-08-10       Impact factor: 9.461

6.  Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity.

Authors:  David A Hess; Todd E Meyerrose; Louisa Wirthlin; Timothy P Craft; Phillip E Herrbrich; Michael H Creer; Jan A Nolta
Journal:  Blood       Date:  2004-06-03       Impact factor: 22.113

7.  Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity.

Authors:  Benjamin J Capoccia; Debra L Robson; Krysta D Levac; Dustin J Maxwell; Sarah A Hohm; Marian J Neelamkavil; Gillian I Bell; Anargyros Xenocostas; Daniel C Link; David Piwnica-Worms; Jan A Nolta; David A Hess
Journal:  Blood       Date:  2009-03-26       Impact factor: 22.113

8.  Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes.

Authors:  Veronika S Urbán; Judit Kiss; János Kovács; Elen Gócza; Virág Vas; Eva Monostori; Ferenc Uher
Journal:  Stem Cells       Date:  2007-10-11       Impact factor: 6.277

9.  The adult mouse and human pancreas contain rare multipotent stem cells that express insulin.

Authors:  Simon R Smukler; Margot E Arntfield; Rozita Razavi; George Bikopoulos; Phillip Karpowicz; Raewyn Seaberg; Feihan Dai; Simon Lee; Rosemary Ahrens; Paul E Fraser; Michael B Wheeler; Derek van der Kooy
Journal:  Cell Stem Cell       Date:  2011-03-04       Impact factor: 24.633

10.  Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide.

Authors:  Michael J Haller; Clive H Wasserfall; Maigan A Hulme; Miriam Cintron; Todd M Brusko; Kieran M McGrail; Theresa M Sumrall; John R Wingard; Douglas W Theriaque; Jonathan J Shuster; Mark A Atkinson; Desmond A Schatz
Journal:  Diabetes Care       Date:  2011-10-19       Impact factor: 19.112

  10 in total
  8 in total

Review 1.  Human β-cell regeneration: progress, hurdles, and controversy.

Authors:  Agata Jurczyk; Rita Bortell; Laura C Alonso
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-04       Impact factor: 3.243

2.  Direct comparison of the abilities of bone marrow mesenchymal versus hematopoietic stem cells to reverse hyperglycemia in diabetic NOD.SCID mice.

Authors:  Edith J Arany; Muhammad Waseem; Brenda J Strutt; Astrid Chamson-Reig; Adam Bernardo; Elizabeth Eng; David J Hill
Journal:  Islets       Date:  2018-08-15       Impact factor: 2.694

Review 3.  A survival Kit for pancreatic beta cells: stem cell factor and c-Kit receptor tyrosine kinase.

Authors:  Zhi-Chao Feng; Matthew Riopel; Alex Popell; Rennian Wang
Journal:  Diabetologia       Date:  2015-02-03       Impact factor: 10.122

4.  Human adipose-derived stromal/stem cells protect against STZ-induced hyperglycemia: analysis of hASC-derived paracrine effectors.

Authors:  Tatsuyoshi M Kono; Emily K Sims; Dan R Moss; Wataru Yamamoto; Geonyoung Ahn; Julie Diamond; Xin Tong; Kathleen H Day; Paul R Territo; Helmut Hanenberg; Dmitry O Traktuev; Keith L March; Carmella Evans-Molina
Journal:  Stem Cells       Date:  2014-07       Impact factor: 6.277

5.  Discovery of metabolite biomarkers: flux analysis and reaction-reaction network approach.

Authors:  Limin Li; Hao Jiang; Yushan Qiu; Wai-Ki Ching; Vassilios S Vassiliadis
Journal:  BMC Syst Biol       Date:  2013-12-17

Review 6.  Targeting endothelial cell metabolism for cardio-protection from the toxicity of antitumor agents.

Authors:  Lucia Morbidelli; Sandra Donnini; Marina Ziche
Journal:  Cardiooncology       Date:  2016-03-15

Review 7.  Efficacy of Stem Cell Application in Diabetes Mellitus: Promising Future Therapy for Diabetes and Its Complications.

Authors:  Faten R Bani Hamad; Neelam Rahat; Kavya Shankar; Nicholas Tsouklidis
Journal:  Cureus       Date:  2021-02-26

Review 8.  Clinical Efficacy of Stem Cell Therapy for Diabetes Mellitus: A Meta-Analysis.

Authors:  Ahmed El-Badawy; Nagwa El-Badri
Journal:  PLoS One       Date:  2016-04-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.